Viatris stock

VTRS · NASDAQ · USD

Compare Viatris
$20.45Change from previous close: −1.40%Absolute change: −$0.29

Close · November 17, 2026

Price history

+93.25% over the period

1 year: from $10.66 (November 17, 2025) to $20.60 (November 17, 2026), +93.25%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$20.60
October 30, 2026$19.04
September 30, 2026$17.72
August 31, 2026$16.51
July 31, 2026$17.56
June 30, 2026$15.88
May 29, 2026$16.26
April 30, 2026$14.94
March 31, 2026$13.51
February 27, 2026$14.93
January 30, 2026$13.09
December 31, 2025$12.45
November 28, 2025$10.69
November 17, 2025$10.66

At a glance

TickerLandia's take on Viatris

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$10.15
52-wk high$21.20

−3.54% from the 52-week high

Analysts · 12 analysts

Average target$21.30+4.16% vs. price

Buy 7 · Hold 4 · Sell 1 · Buy

TickerLandia Fingerprint: Viatris

Compared with similar companies: very strong momentum and very low financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.

4 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

The financials

The business in numbers

Revenue

$3.75B

Latest quarter · Q3 2026

Net income

-$325.3M

Latest quarter · Q3 2026

Quarterly net margin

-8.7%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$23.58B
Volume
745.8K
Daily trading
€163.31M
Dividend yield
2.35%

How Viatris is changing

All results
  • Revenue grew 3.7% a year on average over the last 5 years

  • Operating margin fell from 16.9% to 8.6%

  • Shares outstanding up 94.7% in 5 years

Returns

Viatris returns with dividends

$1,000 invested in Viatris 5 years ago, on November 17, 2021, would be worth $1,861 today with dividends reinvested: +86.14% in total, +13.23% per year. On price alone it would be $1,509 (+50.92%).

PeriodViatrisS&P 500$1,000 becomes
1 month+12.81%−3.17%$1,128
6 months+24.09%+0.11%$1,241
Year to date+65.46%+8.34%$1,655
1 year+99.97%+11.15%$2,000
3 years+147.07%+64.30%$2,471
5 years+86.14%+58.18%$1,861
10 years−31.36%+239.10%$686

Over the last 6 months it has done better than 61% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Viatris: technical analysis

Viatris is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 73.1% below its highest close since January 2, 1990 ($76.06, April 24, 2015).

Trend
Upward
RSI (14 sessions)
64
Between 30 and 70
vs 200-session average
+25.35%

Support and resistance

Price areas where Viatris has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$20.45
  3. Support$18.41−9.98%2 touches, last on September 29, 2026
  4. Support$17.97−12.15%2 touches, last on October 23, 2026
  5. Support$17.53−14.28%2 touches, last on May 14, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.64
Volatility (60 sessions, annualised)
26.5%
Largest fall in the last year
−19.65%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Viatris: seasonality

Average monthly price change over 37 years

+0.3%Jan−0.2%Feb−0.6%Mar−1.0%Apr+1.7%May−0.9%Jun+0.0%Jul+1.8%Aug+0.5%Sep+1.4%Oct+5.1%Nov+3.2%Dec

Over the last 37 years, the strongest month for Viatris has been November: +5.10% on average, positive in 24 years out of 36. The weakest has been April: −0.96% on average, positive in 14 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+0.32%−0.67%17 of 36
February−0.24%+0.21%19 of 37
March−0.57%−0.14%18 of 37
April−0.96%−3.10%14 of 37
May+1.66%+0.52%20 of 37
June−0.87%−0.41%17 of 37
July+0.01%+1.07%21 of 37
August+1.83%+0.65%20 of 37
September+0.52%+0.28%19 of 37
October+1.37%−0.09%18 of 37
November+5.10%+4.02%24 of 36
December+3.19%+3.84%23 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Viatris and its competitors

Viatris Inc. is based in Canonsburg, Pennsylvania, and has existed since its founding in 1961. Together with its subsidiaries, the healthcare company develops and sells prescription brand drugs, generic drugs, complex generics and biosimilars in areas such as cardiovascular, CNS and anesthesia, diabetes and metabolism, oncology, and respiratory and allergy. Its brands include Lipitor, Viagra, Lyrica and EpiPen Auto-Injector, supplied as oral solid doses, injectables and complex dosage forms to pharmacies, wholesalers, payers, insurers, governments and institutions.

Headquarters
Canonsburg, United States
Employees
30,000
Founded
1961
Chief executive
Scott Smith
Viatris and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ViatrisVTRS$23.58B——+24.09%
United TherapeuticsUTHR$25.04B39.4%22.2+2.73%
Neurocrine BiosciencesNBIX$16.73B26.6%24.5+4.73%
ZoetisZTS$33.92B37.9%14.1+12.48%
Teva Pharmaceutical IndustriesTEVA$49.67B19.8%99.0+24.29%
Hims & Hers HealthHIMS$4.13B-6.4%—−29.94%

Same industry or related industries, similar size. Compare Viatris with its competitors · Full profile